Latest Healthcare News

Biotron Limited is set to acquire Sedarex Limited, gaining global patents for SedRx, a next-generation general anaesthetic, supported by a $2.5 million capital raising to fund regulatory and development milestones.

Bod Science reports a $576k cash outflow in Q1 FY2026 amid ongoing administration and delays in Biortica audit completion. The company plans a shareholder vote in November to approve its acquisition of Biortica and exit from administration.

Bod Science Limited reported a $576,000 net operating cash outflow for the September quarter, sustained by funding from Biortica Agrimed Limited under a Deed of Company Arrangement as it pursues a backdoor listing.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Cann Group Limited has extended the expiry of its National Australia Bank debt facilities by one year to October 2025, maintaining current terms while exploring long-term refinancing options.

Emyria has secured a multi-year funding extension with Medibank to launch its Empax mental health programs in Brisbane, marking a key step in its national expansion. This insurer-backed initiative aims to improve access to treatment for complex conditions like treatment-resistant depression and PTSD.

Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Argenica Therapeutics reports encouraging functional improvements in stroke patients treated with ARG-007, setting the stage for a targeted Phase 2b trial focused on patient-centered outcomes.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.